Broad-spectrum antiviral drug

AB Science announces the publication of an article in the world-renowned journal Science that confirms potential of masitinib as a treatment of Covid-19 with anti-viral activity against SARS-CoV-2 and all tested variants of concern

Retrieved on: 
Tuesday, July 20, 2021
Health sciences, Medicine, Health, Sarbecovirus, Zoonoses, Antiviral drugs, Biocides, 3C-like protease, Masitinib, Severe acute respiratory syndrome coronavirus 2, Broad-spectrum antiviral drug, COVID-19

This direct-acting antiviral mechanism of action distinguishes masitinib from many other COVID-19 drugs, including polymerase inhibitors or monoclonal antibodies.

Key Points: 
  • This direct-acting antiviral mechanism of action distinguishes masitinib from many other COVID-19 drugs, including polymerase inhibitors or monoclonal antibodies.
  • Also reported for the first time are data on the effectiveness of masitinib as an anti-SARS-CoV-2 drug in animals.
  • Remarkably, masitinib was also effective, in vitro, against all tested variants of concern, including the rapidly spreading Alpha, Beta and Gamma variants.
  • Thus, masitinib is a relatively broad-spectrum antiviral with potential activity against multiple viruses that rely on 3CL protease to complete their life cycle.

Synairgen announces results of in vitro studies showing antiviral activity of interferon beta against key SARS-CoV-2 variants

Retrieved on: 
Monday, May 24, 2021
Antiviral drugs, Medical specialties, Biology, Interferon, Branches of biology, Broad-spectrum antiviral drug, Variants of SARS-CoV-2, Antiviral protein, COVID-19 drug repurposing research

Interferon beta ('IFN-beta') is a naturally-occurring protein, which orchestrates the body's antiviral responses by triggering the production of hundreds of antiviral proteins which act across the viral replication cycle to confer broad-spectrum antiviral activity.

Key Points: 
  • Interferon beta ('IFN-beta') is a naturally-occurring protein, which orchestrates the body's antiviral responses by triggering the production of hundreds of antiviral proteins which act across the viral replication cycle to confer broad-spectrum antiviral activity.
  • In vitro experiments were conducted at Viroclinics-DDL in the Netherlands to confirm that SNG001 had activity against the B.1.1.7 (UK or Kent) and B.1.351 (South African) variants.
  • Concentrations, readily achievable following inhaled delivery of interferon beta, that gave 90% inhibition (IC90) were 3.2, 4.0 and 3.4 IU/mL respectively.
  • Richard Marsden, CEO of Synairgen, added: As expected, these data confirm that SNG001 is a broad-spectrum antiviral product, now also demonstrating applicability against SARS-CoV-2 variants.

Synairgen announces results of in vitro studies showing antiviral activity of interferon beta against key SARS-CoV-2 variants

Retrieved on: 
Monday, May 24, 2021
Antiviral drugs, Medical specialties, Biology, Interferon, Branches of biology, Broad-spectrum antiviral drug, Variants of SARS-CoV-2, Antiviral protein, COVID-19 drug repurposing research

Interferon beta ('IFN-beta') is a naturally-occurring protein, which orchestrates the body's antiviral responses by triggering the production of hundreds of antiviral proteins which act across the viral replication cycle to confer broad-spectrum antiviral activity.

Key Points: 
  • Interferon beta ('IFN-beta') is a naturally-occurring protein, which orchestrates the body's antiviral responses by triggering the production of hundreds of antiviral proteins which act across the viral replication cycle to confer broad-spectrum antiviral activity.
  • In vitro experiments were conducted at Viroclinics-DDL in the Netherlands to confirm that SNG001 had activity against the B.1.1.7 (UK or Kent) and B.1.351 (South African) variants.
  • Concentrations, readily achievable following inhaled delivery of interferon beta, that gave 90% inhibition (IC90) were 3.2, 4.0 and 3.4 IU/mL respectively.
  • Richard Marsden, CEO of Synairgen, added: As expected, these data confirm that SNG001 is a broad-spectrum antiviral product, now also demonstrating applicability against SARS-CoV-2 variants.

AIkido Pharma Has Pending Data Results on June 4th, with Strongest Balance Sheet in Its History While Trading Below Cash

Retrieved on: 
Thursday, May 20, 2021
Medical specialties, Health sciences, Health, Zoonoses, Antiviral drugs, Broad-spectrum antiviral drug, Novartis, Virus, COVID-19, Ebola

Novartis recently announced positive results in Phase III clinical trials.

Key Points: 
  • Novartis recently announced positive results in Phase III clinical trials.
  • This assumption is reinforced by the test results coming back from Novartis.
  • The study includes both novel and repurposed drugs.\nThe anti-viral program is a continuing mission to find treatment options for Coronavirus, Influenza, and Ebola.
  • Researchers have already identified a SKI complex as a potential broad-spectrum antiviral target with a functional link to viral proteins.\nEarly results from the project are encouraging.

Innovation Pharma Announces Brilacidin Abstract Accepted for Oral Presentation at the American Society for Virology’s Annual Meeting

Retrieved on: 
Wednesday, April 7, 2021
Antiviral drugs, Virology, Medical specialties, Microbiology, Coronavirus, Coronavir, Severe acute respiratory syndrome coronavirus, Broad-spectrum antiviral drug, Novel coronavirus, COVID-19, Severe acute respiratory syndrome–related coronavirus

Brilacidin was shown to exhibit a potent inhibitory effect on SARS-CoV-2, the novel coronavirus responsible for COVID-19, as well as different types of alphaviruses, in cell culture.

Key Points: 
  • Brilacidin was shown to exhibit a potent inhibitory effect on SARS-CoV-2, the novel coronavirus responsible for COVID-19, as well as different types of alphaviruses, in cell culture.
  • Further details on the Brilacidin ASV 2021 presentation will be forthcoming.
  • An effective broad-spectrum antiviral is largely absent in medicine today, commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals.
  • So it is extremely rewarding to see Brilacidin exhibit consistent in vitro inhibition against coronaviruses and alphaviruses.

AIkido Pharma Provides Update on its Antiviral Platform, Including the Virus That Causes COVID-19

Retrieved on: 
Monday, February 22, 2021
Antiviral drugs, Medical specialties, Medicine, Health sciences, Zoonoses, Sarbecovirus, Bat virome, Broad-spectrum antiviral drug, Viruses, Coronavirus, Severe acute respiratory syndrome coronavirus, Coronavir

These new compounds are currently being tested against Influenza virus with testing on SARS-CoV-2 in the near future.

Key Points: 
  • These new compounds are currently being tested against Influenza virus with testing on SARS-CoV-2 in the near future.
  • Subsequently, the top analogs from eachseries of leadcompounds will be selected for tests of their anti-viral effects in a SARS-CoV-2 mouse model.
  • AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics.
  • The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

BioCryst Provides Update on Galidesivir Program

Retrieved on: 
Tuesday, December 22, 2020
Antiviral drugs, Nucleosides, Ebola, Galidesivir, Biology, Life sciences, Medical specialties, Biodefense, National Institute of Allergy and Infectious Diseases, Broad-spectrum antiviral drug, BioCryst Pharmaceuticals

We are encouraged by the first patient data with galidesivir and the growing body of evidence that galidesivir could be an important broad-spectrum antiviral.

Key Points: 
  • We are encouraged by the first patient data with galidesivir and the growing body of evidence that galidesivir could be an important broad-spectrum antiviral.
  • We appreciate the governments continued investment to investigate galidesivir as a biodefense drug, said Jon Stonehouse, chief executive officer of BioCryst.
  • BioCryst is engaged in ongoing discussions with NIAID to define specific further galidesivir studies that NIAID would support.
  • This press release contains forward-looking statements, including statements regarding BioCrysts plans and expectations for its galidesivir development program.

DGAP-News: CytoTools receives confirmation of efficacy of DPCOL also against influenza viruses

Retrieved on: 
Monday, December 21, 2020
Health, Medicine, Zoonoses, Epidemiology, Pandemics, Virus, Influenza, Broad-spectrum antiviral drug

Darmstadt, 21 December 2020 - CytoTools AG (ISIN DE000A0KFRJ1), a biotechnology holding company specializing in pharmaceuticals and medical devices, now also has the preliminary results of the test series on the efficacy of the active ingredient DPOCL on influenza viruses.

Key Points: 
  • Darmstadt, 21 December 2020 - CytoTools AG (ISIN DE000A0KFRJ1), a biotechnology holding company specializing in pharmaceuticals and medical devices, now also has the preliminary results of the test series on the efficacy of the active ingredient DPOCL on influenza viruses.
  • Used as an inhalation component, it thus also opens up fundamentally new possibilities in the therapy of viral influenza infections."
  • In the cell culture experiments now completed, the efficacy of DPOCL on influenza viruses was investigated in combination with human cells.
  • This confirms the efficacy of DPOCL on Sars-CoV-2 viruses with an inhibition of over 95 percent.

Cidara Therapeutics to Present Preclinical Data for Influenza AVCs at the 7th ESWI Influenza Conference

Retrieved on: 
Tuesday, December 1, 2020
Biocides, Health, Articles, Antiviral drug, Virus, Broad-spectrum antiviral drug

Cidara is developing a new generation of immunotherapeutic antivirals from its Cloudbreak antiviral platform that couple potent antivirals to a human antibody fragment.

Key Points: 
  • Cidara is developing a new generation of immunotherapeutic antivirals from its Cloudbreak antiviral platform that couple potent antivirals to a human antibody fragment.
  • These long-acting, antiviral conjugates (AVCs) directly inhibit viral proliferation while simultaneously engaging the immune system.
  • Cidara is also advancing preclinical and discovery AVC programs to target other life-threatening viruses, such as RSV, HIV and CoV, including COVID-19.
  • Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections.

Aegis Sciences Corporation Launches Combined Test for SARS-CoV-2 and Influenza A/B Virus

Retrieved on: 
Monday, November 16, 2020
Medical specialties, Medicine, Health, Sarbecovirus, Virology, Severe acute respiratory syndrome, Severe acute respiratory syndrome coronavirus, Coronavirus disease, Influenza, Coinfection, Wuhan flu, Broad-spectrum antiviral drug

NASHVILLE, Tenn., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Aegis Sciences Corporation, a leading healthcare company that provides clinically innovative medication compliance testing and consulting services to providers, has launched a combined test for SARS-CoV-2 and influenza A/B virus for individuals suspected of respiratory viral infection consistent with COVID-19.

Key Points: 
  • NASHVILLE, Tenn., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Aegis Sciences Corporation, a leading healthcare company that provides clinically innovative medication compliance testing and consulting services to providers, has launched a combined test for SARS-CoV-2 and influenza A/B virus for individuals suspected of respiratory viral infection consistent with COVID-19.
  • Since symptoms of respiratory viral infection due to SARS-CoV-2 and influenza can be similar, a multiplex assay serves as a single test to diagnose infection caused by one of three viruses.
  • The combination COVID-19 + FLU A/B test is a reverse transcriptase polymerase chain reaction (RT-PCR) molecular test intended for the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A virus, and/or influenza B virus.
  • With the flu season looming and COVID-19 surging, laboratory testing that can distinguish between SARS-CoV-2 and influenza virus infections and identify coinfection will be critical to patient care and public health response, said Dr. Frank Basile, CEO of Aegis Sciences Corporation.